产后出院时使用拉贝洛尔或硝苯地平后因高血压再入院的情况
这项队列研究纳入2006至2017年分娩并在出院时使用硝苯地平或拉贝洛尔的患者,比较产后6周内因高血压再入院率。拉贝洛尔组再入院率高于硝苯地平组(4.5% vs 2.1%,aOR 1.63,95%CI 1.43-1.85),轻度和重度妊娠期高血压疾病亚组结果一致。
要点
- 出院时使用拉贝洛尔者产后因高血压再入院率高于使用硝苯地平者(4.5% vs 2.1%)。
- 轻度妊娠期高血压疾病亚组再入院率拉贝洛尔组4.5% vs 硝苯地平组2.7%(aOR 1.57)。
- 重度妊娠期高血压疾病亚组再入院率拉贝洛尔组5.7% vs 硝苯地平组3.2%(aOR 1.63)。
核心结论
- 产后出院时使用拉贝洛尔与因高血压再入院风险增加相关,相比使用硝苯地平。
研究设计与样本
- 这项队列研究纳入2006至2017年分娩出院时使用硝苯地平或拉贝洛尔的患者,数据来自大型全国性裁定索赔数据库。
- 共纳入1,582,335例患者,其中出院时单用拉贝洛尔14,112例(0.89%),单用硝苯地平9,001例(0.57%),两药联用1,364例(0.09%)。
- 排除无叠加子痫前期的慢性高血压患者,比较基于药物分组,采用逻辑回归模型校正预设混杂因素,并按妊娠期高血压疾病严重程度分层。
主要发现
- 产后因高血压再入院率拉贝洛尔组高于硝苯地平组(641例 vs 185例,4.5% vs 2.1%,aOR 1.63,95%CI 1.43-1.85)。
- 轻度妊娠期高血压疾病亚组再入院率拉贝洛尔组4.5% vs 硝苯地平组2.7%(aOR 1.57,95%CI 1.29-1.93)。
- 重度妊娠期高血压疾病亚组再入院率拉贝洛尔组5.7% vs 硝苯地平组3.2%(261例 vs 72例,aOR 1.63,95%CI 1.43-1.85)。
- 两药联用组再入院率3.1% vs 硝苯地平组2.1%,校正混杂因素后aOR 0.80(95%CI 0.64-0.99)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess whether readmission for hypertension by 6 weeks postpartum differed between patients discharged on nifedipine or labetalol. METHODS: This cohort study included patients with delivery admissions from 2006 to 2017 who were discharged from the hospital on nifedipine or labetalol and were included in a large, national adjudicated claims database. We identified patients' discharge medication based on filled outpatient prescriptions. We compared rates of hospital readmission for hypertension between patients discharged postpartum on labetalol alone, nifedipine alone, or combined nifedipine and labetalol. Patients with chronic hypertension without superimposed preeclampsia were excluded. Comparisons based on medication were performed using logistic regression models with adjustment for prespecified confounders. Comparisons were also stratified by hypertensive disorder of pregnancy severity. RESULTS: Among 1,582,335 patients overall, 14,112 (0.89%) were discharged postpartum on labetalol, 9,001 (0.57%) on nifedipine, and 1,364 (0.09%) on both medications. Postpartum readmissions for hypertension were more frequent for patients discharged on labetalol compared with nifedipine (641 patients vs 185 patients, 4.5% vs 2.1%, adjusted odds ratio [aOR] 1.63, 95% CI 1.43-1.85). Readmissions for hypertension were more frequent for patients discharged on labetalol compared with nifedipine for both mild (4.5% vs 2.7%, aOR 1.57, 95% CI 1.29-1.93) and severe hypertensive disorders of pregnancy (261 patients vs 72 patients, 5.7% vs 3.2%, aOR 1.63, 95% CI 1.43-1.85). Readmissions for hypertension were more frequent on combined nifedipine and labetalol compared with nifedipine (3.1% vs 2.1%), but the odds were lower after confounder adjustment (aOR 0.80, 95% CI 0.64-0.99). CONCLUSION: Postpartum discharge on labetalol was associated with increased risk of readmission for hypertension compared with discharge on nifedipine.
引用
- Do SC, Leonard SA, Kan P, et al. Postpartum Readmission for Hypertension After Discharge on Labetalol or Nifedipine. Obstet Gynecol. 2022. PMID: 36075068. doi:10.1097/AOG.0000000000004918
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。